Emerging therapies for the prevention of acute respiratory distress syndrome

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 4, 2015, Pages 173-187

  Ruthman, Carl A ^a   Festic, Emir ^a  

^a MAYO CLINIC   (United States)

Author keywords

acute respiratory distress syndrome; pharmacology; prevention

Indexed keywords

DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ADRENOMEDULLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA1A INTERFERON; BLEOMYCIN; CAPTOPRIL; CORTICOSTEROID; CURCUMIN; ENDOTOXIN; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KERATINOCYTE GROWTH FACTOR; ROSIGLITAZONE; SALBUTAMOL; SALMETEROL; SODIUM CHLORIDE; THROMBOXANE;

ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MORTALITY; PATHOPHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTOR; ACUTE ABDOMEN; ADULT RESPIRATORY DISTRESS SYNDROME; ALCOHOL ABUSE; APOPTOSIS; ARTIFICIAL VENTILATION; ASPIRATION; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ESOPHAGUS RESECTION; FRACTURE; HEART SURGERY; HOSPITAL ADMISSION; HOSPITALIZATION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INTENSIVE CARE UNIT; LUNG BURN; LUNG CIRCULATION; LUNG CONTUSION; LUNG DYSPLASIA; LUNG FIBROSIS; LUNG HEMODYNAMICS; MACROPHAGE; MORBIDITY; MULTICENTER STUDY (TOPIC); NEAR DROWNING; NEBULIZER; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; PANCREATITIS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEPSIS; SHOCK; STANDARDIZATION; SYSTEMIC THERAPY; TRAUMATIC BRAIN INJURY; VASCULAR SURGERY;

ADMINISTRATION, INHALATION; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS;

EID: 84937037360     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815585716     Document Type: Review

References (96)

1. Arnaud C. Veillard N. Mach F. (2005) Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 5: 127–134.
2. Avasarala S. Zhang F. Liu G. Wang R. London S.D. London L. (2013) Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PloS One 8: e57285.
3. Bajwa E.K. Malhotra C.K. Thompson B.T. Christiani D.C. Gong M.N. (2012) Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study. Crit Care Med 40(5): 1470–1477.
4. Bao S. Wang Y. Chaudhuri P. Doseff A.I. Marsh C.B. Knoell D.L. (2005) Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. American Journal of Physiology, Lung Cellular and Molecular Physiology 288(1): L36–L42.
5. Beitler J. Schoenfeld D. Thompson B. (2014) Preventing ARDS: progress, promise, and pitfalls. Chest 146: 1102–1113.
6. Bellingan G. Maksimow M. Howell D. Stotz M. Beale R. Beatty M. (2014) The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2: 98–107.
7. Belvisi M. Hele D. (2008) Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134: 152–157.
8. Bosma K. Taneja R. Lewis J. (2010) Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches. Drugs 70: 1255–1282.
9. Brower R. Matthay M. Morris A. Schoenfeld D. Thompson B.T. Wheeler A.; the Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301–1308.
10. Brown J. Plutzky J. (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115: 518–533.
11. Bulger E. May S. Kerby J. Emerson S. Stiell I. Schreiber M. (2011) Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg 253: 431–441.
12. Cepkova M. Matthay M. (2006) Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 21: 119–143.
13. Chen W. Janz D. Bastarache J. May A. O–Neal H. Bernard G. (2014) Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. Critical Care Med 43(4): 801–807.
14. Conhaim R. Mangino M. Dovi W. Watson K. Warner T. Harms B. (2010) Microthrombus formation may trigger lung injury after acute blood loss. Shock 34: 601–607.
15. Conhaim R. Watson K. Dovi W. Bates M. (2014) Inhaled thrombolytics reduce lung microclot and leukocyte infiltration after acute blood loss. Shock 41: 528–536.
16. Cuschieri J. Gourlay D. Garcia I. Jelacic S. Maier R. (2002) Hypertonic preconditioning inhibits macrophage responsiveness to endotoxin. J Immunol 168: 1389–1396.
17. Deitch E. Shi H. Feketeova E. Hauser C. Xu D. (2003) Hypertonic saline resuscitation limits neutrophil activation after trauma-hemorrhagic shock. Shock 19: 328–333.
18. Dwivedi A. Wu R. Nguyen E. Higuchi S. Wang H. Krishnasastry K. (2007) Adrenomedullin and adrenomedullin binding protein-1 prevent acute lung injury after gut ischemia-reperfusion. J Am Coll Surg 205: 284–293.
19. Elkins M. Robinson M. Rose B. Harbour C. Moriarty C. Marks G. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229–240.
20. Erlich J. Talmor D. Cartin-Ceba R. Gajic O. Kor D. (2011) Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 139: 289–295.
21. Estenssoro E. Dubin A. Laffaire E. Canales H. Saenz G. Mosienco M. (2002) Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med 30: 2450–2456.
22. Falagas M. Makris G. Matthaiou D. Rafailidis P. (2008) Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61: 774–785.
23. Festic E. Bansal V. Kor D. Gajic O. (2013a) SpO2/FiO2 ratio on hospital admission is an indicator of early acute respiratory distress syndrome development among patients at risk. J Intensive Care Med 30(4): 209–216.
24. Festic E. Ortiz-Diaz E. Lee A. Li G. Kor D Adebola A. (2013b) Prehospital use of inhaled steroids and incidence of acute lung injury among patients at risk. J Crit Care 28: 985–991.
25. Forsgren P. Modig J. Dahlback C. Axelsson B. (1990) Prophylactic treatment with an aerosolized corticosteroid liposome in a porcine model of early ARDS induced by endotoxaemia. Acta Chir Scand 156: 423–431.
26. Frieri M. (1999) Corticosteroid effects on cytokines and chemokines. Allergy Asthma Proc 20: 147–159.
27. Gajic O. Dabbagh O. Park P. Adesanya A. Chang S. Hou P. (2011) Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Resp Crit Care Med 183: 462–470.
28. Gajic O. Rana R. Winters J. Yilmaz M. Mendez J. Rickman O. (2007) Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Resp Crit Care Med 176: 886–891.
29. Greenwood J. Mason J. (2007) Statins and the vascular endothelial inflammatory response. Trends Immunol 28: 88–98.
30. Hayes M. Masterson C. Devaney J. Barry F. Elliman S. O–Brien T. (2014) Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat. Anesthesiology 122(2): 363–373.
31. Honiden S. Gong M. (2009) Diabetes, insulin, and development of acute lung injury. Crit Care Med 37: 2455–2464.
32. Idell S. Kueppers F. Lippmann M. Rosen H. Niederman M. Fein A. (1987) Angiotensin converting enzyme in bronchoalveolar lavage in ARDS. Chest 91: 52–56.
33. Itoh T. Obata H. Murakami S. Hamada K. Kangawa K. Kimura H. (2007) Adrenomedullin ameliorates lipopolysaccharide-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 293: L446–L452.
34. Jacobson J. Barnard J. Grigoryev D. Ma S. Tuder R. Garcia J. (2005) Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288: L1026–L1032.
35. Jansson A. Eriksson C. Wang X. (2005) Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats. Vascul Pharmacol 43: 101–111.
36. Kellett F. Robert N. (2011) Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Resp Med 105: 1831–1835.
37. Khan H. Belsher J. Yilmaz M. Afessa B. Winters J. Moore S. (2007) Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 131: 1308–1314.
38. Kor D. Erlich J. Gong M. Malinchoc M. Carter R. Gajic O. (2011a) Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 39: 2393–2400.
39. Kor D. Lingineni R. Gajic O. Park P. Blum J. Hou P. (2014) Predicting risk of postoperative lung injury in high-risk surgical patients: a multicenter cohort study. Anesthesiology 120: 1168–1181.
40. Kor D. Talmor D. Banner-Goodspeed V. Carter R. Hinds R. Park P. (2012) Lung injury prevention with aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open 2(5).
41. Kor D. Warner D. Alsara A. Fernandez-Perez E. Malinchoc M. Kashyap R. (2011b) Derivation and diagnostic accuracy of the surgical lung injury prediction model. Anesthesiology 115: 117–128.
42. Kovalovsky D. Refojo D. Holsboer F. Arzt E. (2000) Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol 109: 23–29.
43. Kruger P. Fitzsimmons K. Cook D. Jones M. Nimmo G. (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32: 75–79.
44. Lauterburg B. Corcoran G. Mitchell J. (1983) Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest 71: 980–991.
45. Lee J. Krasnodembskaya A. McKenna D. Song Y. Abbott J Matthay M. (2013) Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Resp Crit Care Med 187: 751–760.
46. Lee J. Rocco P. Pelosi P. (2014) Mesenchymal stem cell therapy for acute respiratory distress syndrome: a light at the end of the tunnel? Anesthesiology 122(2): 238–240.
47. Levitt J. Bedi H. Calfee C. Gould M. Matthay M. (2009) Identification of early acute lung injury at initial evaluation in an acute care setting prior to the onset of respiratory failure. Chest 135: 936–943.
48. Li G. Malinchoc M. Cartin-Ceba R. Venkata C. Kor D. Peters G. (2011) Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am J Resp Crit Care Med 183: 59–66.
49. Liao J. (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110: 285–288.
50. Liu H. Zhao J. (2002) An experimental study of therapeutic effect of ACEI on chemical-induced ARDS in rats. Zhonghua Yu Fang Yi Xue Za Zhi 36: 93–96.
51. Looney M. Nguyen J. Hu Y. Van Ziffle J. Lowell C. Matthay M. (2009) Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 119: 3450–3461.
52. Marshall R. Gohlke P. Chambers R. Howell D. Bottoms S. Unger T. (2004) Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 286: L156–L164.
53. Marshall R. Webb S. Bellingan G. Montgomery H. Chaudhari B. McAnulty R. (2002) Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Resp Crit Care Med 166: 646–650.
54. Matthay M. Folkesson H. Clerici C. (2002) Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 82: 569–600.
55. Matthay M. Ware L. Zimmerman G. (2012) The acute respiratory distress syndrome. J Clin Invest 122: 2731–2740.
56. Mei S. Haitsma J. Dos Santos C. Deng Y. Lai P. Slutsky A. (2010) Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Resp Crit Care Med 182: 1047–1057.
57. Miller A. Elamin E. Suffredini A. (2014) Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med 42: 413–419.
58. Miller A. Rivero A. Ziad S. Smith D. Elamin E. (2009) Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 30: 249–256.
59. National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network et al. (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354: 2564–2575.
60. O–Neal H. Jr Koyama T. Koehler E. Siew E. Curtis B. Fremont R. (2011) Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 39: 1343–1350.
61. Ohkubo T. Chapman N. Neal B. Woodward M. Omae T. Chalmers J. (2004) Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Resp Crit Care Med 169: 1041–1045.
62. Ortiz-Diaz E. Festic E. Gajic O. Levitt J. (2013) Emerging pharmacological therapies for prevention and early treatment of acute lung injury. Semin Resp Crit Care Med 34: 448–458.
63. Perkins G.D. Gates S. Park D. Gao F. Knox C. Holloway B. (2014) BALTI-Prevention Collaborators. The Beta Agonist Lung Injury Trial Prevention: a randomized controlled trial. Am J Respir Crit Care Med 189: 674–683.
64. Phua J. Badia J. Adhikari N. Friedrich J. Fowler A. Singh J. (2009) Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. Am J Resp Crit Care Med 179: 220–227.
65. Ranieri V. Rubenfeld G. Thompson B. Ferguson N. Caldwell E. Fan E. (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526–2533.
66. Rivers E. Nguyen B. Havstad S. Ressler J. Muzzin A. Knoblich B. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377.
67. Rosenthal V. Rodrigues C. Alvarez-Moreno C. Madani N. Mitrev Z. Ye G. (2012) Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in adult intensive care units from 14 developing countries of four continents: findings of the International Nosocomial Infection Control Consortium. Crit Care Med 40: 3121–3128.
68. Seam N. Meduri G. Wang H. Nylen E. Sun J. Schultz M. (2012) Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med 40: 495–501.
69. Soltan-Sharifi M. Mojtahedzadeh M. Najafi A. Khajavi M. Rouini M. Moradi M. (2007) Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol 26: 697–703.
70. Song C. Suzuki S. Kubo H. Chida M. Hoshikawa Y. Tabata T. (2004) Effects of antiplatelet agents on pulmonary haemodynamic response to fMLP in endotoxin primed rats. Thorax 59: 39–44.
71. Steinberg K. Hudson L. Goodman R. Hough C. Lanken P. Hyzy R. (2006) Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354: 1671–1684.
72. Thompson B. (2003) Glucocorticoids and acute lung injury. Crit Care Med 31(4 Suppl.): S253's257.
73. Thompson B. (2014) The Berlin definition of ARDS versus pathological evidence of diffuse alveolar damage. Am J Resp Crit Care Med 187: 675–677.
74. Toy P. Gajic O. Bacchetti P. Looney M. Gropper M. Hubmayr R. (2012) Transfusion-related acute lung injury: incidence and risk factors. Blood 119: 1757–1767.
75. Trillo-Alvarez C.A. Kashyap R. Kojicic M. Li G. Thakur S. Cartin-Cebal R. (2009) Chronic use of angiotensin pathway inhibitors is associated with a decreased risk of acute respiratory distress syndrome. American Thoracic Society, San Diego. Am J Respir Crit Care Med 179: A4638.
76. Truwit J. Bernard G. Steingrub J. Matthay M. Liu K. Albertson T. (2014) Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 370: 2191–2200.
77. Walther S. Jansson I. Berg S. Lennguist S. (1992) Pulmonary granulocyte accumulation is reduced by nebulized corticosteroid in septic pigs. Acta Anaesthesiol Scand 36: 651–655.
78. Walther S. Jansson I. Berg S. Olsson R. Lennquist S. (1993) Corticosteroid by aerosol in septic pigs–effects on pulmonary function and oxygen transport. Intensive Care Med 19: 155–160.
79. Wang J. Zhang L. Walther S. (2002) Inhaled budesonide in experimental chlorine gas lung injury: influence of time interval between injury and treatment. Intensive Care Medicine 28: 352–357.
80. Wang J. Zhang L. Walther S. (2004) Administration of aerosolized terbutaline and budesonide reduces chlorine gas-induced acute lung injury. J Trauma 56: 850–862.
81. Watkins T. Lemos-Filho L. Dabbagh O. Chang S. Park P. Gong M. (2011) Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and clinical outcomes among patients at-risk for acute lung injury. American Thoracic Society, Denver, CO. Am J Respir Crit Care Med 183: A5598.
82. Williams B. Hubmayr R. Plataki M. (2012) The use of hypertonic saline aerosols as cytoprotective adjunct in murine hydrochloric aspiration and ventilation induced injury. Am Thorac Soc:A5446.
83. Wohlauer M. Moore E. Silliman C. Fragoso M. Gamboni F Harr J. (2012) Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Critical Care Med 40: 2647–2653.
84. Wosten-van Asperen R. Lutter R. Haitsma J. Merkus M. van Woensel J. van der Loos C. (2008) ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur Resp J 31: 363–371.
85. Yano T. Deterding R. Simonet W. Shannon J. Mason R. (1996) Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Resp Cell Mol Biol 15: 433–442.
86. Yao S. Feng D. Wu Q. Li K. Wang L. (2008) Losartan attenuates ventilator-induced lung injury. J Surg Res 145: 25–32.
87. Yealy D. Kellum J. Huang D. Barnato A. Weissfeld L. Pike F. (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370: 1683–1693.
88. Yiming M. Lederer D. Sun Li. Huertas A. Issekutz A. Bhattacharya S. (2008) Platelets enhance endothelial adhesiveness in high tidal volume ventilation. Am J Resp Cell Mol Biol 39: 569–575.
89. Young E. (2008) The anti-inflammatory effects of heparin and related compounds. Thrombosis Res 122: 743–752.
90. Yu S. Christiani D. Thompson B. Bajwa E. Gong M. (2013) Role of diabetes in the development of acute respiratory distress syndrome. Critical Care Med 41: 2720–2732.
91. Yu Z. Ouyang J. Li Y. (2009) Dexamethasone attenuated endotoxin-induced acute lung injury through inhibiting expression of inducible nitric oxide synthase. Clin Hemorheol Microcirc 41: 117–125.
92. Zallen G. Moore E. Tamura D. Johnson J. Biffl W. Silliman C. (2000) Hypertonic saline resuscitation abrogates neutrophil priming by mesenteric lymph. J Trauma 48: 45–48.
93. Zarbock A. Ley K. (2009) The role of platelets in acute lung injury (ALI). Front Biosci 14: 150–158.
94. Zarbock A. Singbartl K. Ley K. (2006) Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116: 3211–3219.
95. Zhu Y. Feng X. Abbott J. Fang X. Hao Q. Monsel A. (2014) Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells 32: 116–125.
96. Zingg U. Hofer C. Seifert B. Metzger U. Zollinger A. (2007) High dose N-acetylcysteine to prevent pulmonary complications in partial or total transthoracic esophagectomy: results of a prospective observational study. Dis Esophagus 20: 399–405.